Current medical scienceHumansHepatitis BChronicMaleFemale
A Real-World Pharmacological Assessment of Tenofovir Amibufenamide and Tenofovir Alafenamide in 48-Week Chronic Hepatitis B Treatment: Efficacy, Safety, and Cost-Effectiveness.
Li-Li Liu, Yi Feng, Chao-Yi Ren, Yi Liu, Ming-Hui Zhu, Guo-Xiang Hao, Tian-Tian Gao
Published: 202510.1007/s11596-025-00120-5
Abstract
OBJECTIVE: Chronic hepatitis B (CHB), characterized by a significant global disease burden and substantial healthcare costs, remains a critical public health challenge. Although tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF), including…
Preview only. Read the full abstract at the source